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ORIGINAL INVESTIGATION
Use of imaging and clinical data 
to screen for cardiovascular disease 
in asymptomatic diabetics
Carlos Henrique Reis Esselin Rassi1†, Timothy W. Churchill2†, Carlos A. Fernandes Tavares1, 
Mateus Guimaraes Fahel1, Fabricia P. O. Rassi1, Augusto H. Uchida1, Bernardo L. Wajchenberg1, 
Antonio C. Lerario1, Edward Hulten3, Khurram Nasir4, Márcio S. Bittencourt3,5, Carlos Eduardo Rochitte1* 
and Ron Blankstein3
Abstract 
Background: There is increasing evidence to suggest that not all individuals with type 2 diabetes mellitus (T2DM) 
have equal risk for developing cardiovascular disease. We sought to compare the yield of testing for pre-clinical ath-
erosclerosis with various approaches.
Methods: 98 asymptomatic individuals with T2DM without known coronary artery disease (CAD) were enrolled in a 
prospective study and underwent carotid ultrasound, exercise treadmill testing (ETT), coronary artery calcium (CAC) 
scoring, and coronary computed tomography angiography (CTA).
Results: Of 98 subjects (average age 55 ± 6, 64 % female), 43 (44 %) had coronary plaque detectable on CTA, and
38 (39 %) had CAC score >0. By CTA, 16 (16 %) had coronary stenosis ≥50 %, including three subjects with CAC = 0.
Subjects with coronary plaque had greater prevalence of carotid plaque (58 % vs. 38 %, p = 0.01) and greater carotid
intima media thickness (0.80 ± 0.20 mm vs. 0.70 ± 0.11 mm, p = 0.02). Notably, 18 of 55 subjects (33 %) with normal
CTA had carotid plaque. Eight subjects had a positive ETT, of whom five had ≥ 50 % coronary stenosis, two had <50 %
stenosis, and one had no CAD. Among these tests, CAC scoring had the highest sensitivity and specificity for predic-
tion of CAD.
Conclusion: Among asymptomatic subjects with T2DM, a majority (56 %) had no CAD by CTA. When compared to 
CTA, CAC was the most accurate screening modality for detection of CAD, while ETT and carotid ultrasound were 
less sensitive and specific. However, 33 % of subjects with normal coronary CTA had carotid plaque, suggesting that 
screening for carotid plaque might better characterize stroke risk in such patients.
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Background
Cardiovascular disease is the leading cause of morbid-
ity and mortality among individuals with type 2 diabetes 
mellitus (T2DM) [1–3], and diabetics have a higher risk 
of cardiovascular disease as compared to non-diabetics 
with a similar risk factor burden [4]. Moreover, once 
individuals with diabetes present with a coronary heart 
disease event, they experience a worse prognosis than 
non-diabetics [5–8]. Unfortunately, diabetics are also 
known to have a high burden of asymptomatic cardio-
vascular disease. Thus, a wide variety of clinical strategies 
have been proposed for identifying diabetics with coro-
nary artery disease (CAD) before it becomes clinically 
manifest.
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Although screening programs are currently employed 
in asymptomatic diabetics in some clinical settings, their 
potential capability to reduce the rate of adverse cardiac 
outcomes remains unproven [9, 10]. In part, this may be 
due to lower than anticipated event rates in clinical tri-
als, as well as widespread use of preventive therapies irre-
spective of the screening strategy used [11]. While the 
available studies to date support the use of preventive 
therapies for most patients with diabetes, the yield and 
optimal technique for risk stratifying lower-risk individu-
als with diabetes is uncertain. Despite the lack of proven 
benefit, there may remain a role for screening selected 
individuals with diabetes, particularly if the test results 
could favorably influence downstream medical and life-
style therapies. In addition, such screening approaches 
could be useful to provide more individualized assess-
ment when deciding on the intensity of statin therapy, the 
role of aspirin [12], or potentially in the future, the role of 
anti-inflammatory therapies [13] and newer lipid lower-
ing agents [14].
Multiple imaging and laboratory techniques are avail-
able to detect the presence of pre-clinical disease and 
consequently characterize an individual’s risk of future 
cardiovascular events. However, it remains uncertain 
how each of these approaches compare to each other and 
to more expensive imaging techniques in the risk stratifi-
cation of individuals with T2DM. Therefore, using coro-
nary computed tomography angiography (CTA) as the 
reference standard, we sought to compare the use of cor-
onary artery calcium (CAC) scoring, carotid ultrasound, 
and exercise treadmill testing (ETT) for detecting sub-
clinical CAD among a cohort of asymptomatic patients 
with diabetes.
Methods
Patient enrollment
In this prospective cohort study, 98 asymptomatic sub-
jects with T2DM, as defined by American Diabetes Asso-
ciation criteria [15], were recruited between June 2011 
and January 2013 from the Endocrinology Outpatient 
Clinic of the University of São Paulo School of Medicine 
Clinics Hospital. The Ethics Committee of the University 
of São Paulo approved the study, and all patients pro-
vided informed consent during their initial visit.
We included individuals aged 40–65  years with a 
known duration of diabetes of less than 10  years and 
without known prior cardiovascular disease. Exclusion 
criteria included a history of heart failure, ischemic heart 
disease, chest pain, angina, arrhythmia, severe hyperten-
sion (blood pressure >180/100 mmHg), renal or hepatic 
failure, dyspnea at rest, total cholesterol  >350  mg/dL, 
low-density lipoprotein (LDL) cholesterol  >250  mg/dL, 
triglycerides >500 mg/dL, body mass index (BMI) >45 kg/
m2, known neoplasm, pregnancy, dementia, and an 
allergy to iodinated contrast.
Power calculation [16, 17] estimates that a sample size 
of 51 patients would be required for an α of 0.05 and 
power of 0.8 in order to detect a difference among the 
sensitivity of the three screening tests, assuming CAC 
sensitivity to be 90 % [18, 19], ETT sensitivity 30 % [20], 
and carotid ultrasound sensitivity 50 % [21, 22] for detec-
tion of any coronary plaque. ETT has highly variable 
previously reported sensitivities for detection of obstruc-
tive CAD, but to screen for the presence of any plaque, 
including non-obstructive, the sensitivity of ETT is lower 
[20].
Clinical and laboratory evaluation
All clinical and historical data (e.g. diabetes duration) 
were prospectively collected by a study physician prior to 
all imaging and laboratory test results. Laboratory tests 
included fasting glucose and glycosylated hemoglobin, 
total cholesterol and cholesterol fractions, triglycerides, 
creatinine, liver function tests, blood counts, and urine 
and serum human chorionic gonadotropin β (in women 
of childbearing age). Microalbuminuria was measured 
using 24-hour urine collection.
Coronary CTA acquisition and analysis
Coronary CTA and CAC calcium scanning were per-
formed using Toshiba Aquillion One scanner with 320 
detectors, 0.5  mm slice thickness, with gantry rotation 
of 350  ms. Scan coverage in the z-axis ranged from 12 
to 16  cm. For the CTA acquisition, we used tube volt-
age between 80–135 kV and tube current between 200–
580  mA, both selected according to patient BMI. Prior 
to each scan, the patient’s blood pressure and heart rate 
were assessed, and if the heart rate was above 70 beats 
per minute, beta-blockers were administered orally. Fol-
lowing oral beta blocker administration, if the heart rate 
was greater than 64  bpm, intravenous metoprolol was 
administered. We administered 70–100 mL of iodinated 
contrast (Iopamiron 370 mg/ml; Bayer Schering Pharma, 
Berlin, Germany) via an automated injector at a rate of 
5 mL/second. The estimated mean radiation dose for the 
complete CT protocol (coronary CTA plus CAC scan-
ning) was 7.1 mSv per patient.
All coronary CTA images were transferred to a work-
station (Vitrea FX—Vital Image) and analyzed by two 
experienced cardiac imagers who were blinded to all 
other data. A standard 18-segment coronary tree model 
was used [23]. The calcium was calculated according to 
the Agatston protocol [24].
CAD was defined by the presence of any atherosclerotic 
plaque, which was defined as a tissue structure  >1  mm2 
that was contained within and/or adjacent to the coronary 
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artery lumen and could be clearly distinguished from the 
vessel lumen [25]. Plaques were classified according to 
the degree of luminal obstruction. Obstructive CAD was 
defined as the presence of at least one plaque causing a 
luminal reduction of more than 50  % [23]. In cases of a 
disagreement between the two examiners, a third experi-
enced cardiologist mediated a consensus.
Other testing modalities
In addition to CAC scoring and CTA analysis, all subjects 
underwent exercise treadmill testing and carotid ultra-
sonography. Exercise treadmill tests were interpreted by 
an experienced cardiologist who was blinded to all other 
test results. When considering the exercise protocol, 
42 % of subjects exercised using the Bruce protocol, and 
52  % with the modified Bruce protocol. Of the remain-
ing six subjects, five underwent test with Ellestad proto-
col and one with ramp protocol. The ECG was defined 
as positive if there were horizontal or downsloping ST 
depressions greater than 1  mm in two contiguous leads 
(except aVR) 80 ms after the J-point. The ETT was con-
sidered non-diagnostic if subjects did not achieve 85 % of 
the age predicted maximum heart rate.
Carotid ultrasounds were interpreted by an expe-
rienced radiologist. Carotid intima media thickness 
(CIMT) was manually measured in both carotid arter-
ies at end diastole over a 1 cm segment of the common 
carotid artery located 0.5  cm below the carotid-artery 
bulb [26]. CIMT ≥ 1 mm was defined as abnormal [27]. 
Carotid plaque was defined as a focal region protruding 
into the vessel lumen that had either CIMT ≥ 1.5 mm or 
focal wall thickening at least 50 % greater than that of the 
surrounding vessel wall [28].
Statistical analysis
Continuous variables are presented as mean and standard 
deviation or as median and quartiles, as appropriate, and 
tested for significance using two-tailed t test or Kruskal–
Wallis test depending on whether the distribution was 
normal. Categorical variables are presented as absolute 
values and proportions and tested for significance with a 
Chi squared test. To compare the diagnostic yield of vari-
ous screening approached to detect CAD, we calculated 
sensitivity and specificity for each test, using the pres-
ence of any disease by CTA as the reference standard. All 
statistical analysis was done using Stata 12.1 (StataCorp, 
College Station, Texas).
Results
Patient characteristics
Characteristics of study subjects are shown in Table  1, 
stratified by the presence of any CAD. Mean age was 
54.5  years, and 63 (63  %) of subjects were female. The 
mean hemoglobin A1c was 7.3 % and 22 (22 %) were on 
insulin therapy. The mean LDL cholesterol was 116.7 mg/
dL. Fewer than 50  % of subjects were on statin therapy 
or aspirin, and 50 (51 %) were on an ACE inhibitor or an 
ARB. The median 10-year risk was 13.0 % as assessed by 
Framingham Risk Score for coronary heart disease, 8.2 % 
by the 2013 American Heart Association risk calcula-
tor, and 11.4 % by United Kingdom Prospective Diabetes 
Study (UKPDS) risk engine.
Characteristics of patients with coronary artery disease
Subjects with coronary disease on coronary CTA were 
more likely to be older and have hypertension, and 
reported a longer duration of T2DM than subjects with-
out CAD. Among laboratory parameters, only hemoglobin 
A1c was significantly higher among those with CAD 
on CTA. Insulin use was more common among those 
with CAD. Similarly, use of cardiovascular medications, 
including ACE inhibitors or ARBs and statins, was more 
common in subjects with CAD. While there was a trend 
towards increased aspirin use among those with CAD, this 
did not reach statistical significance (p = 0.052).
Coronary CTA findings
Results of the coronary CTA are shown in Table 2. Over-
all, 55 subjects (56 %) had no CAD, while 27 (28 %) had 
non-obstructive plaque (<50 % stenosis). The remaining 
16 subjects (16 %) had at least one coronary stenosis over 
50 %. Among the 43 subjects with any plaque, 27 (63 %) 
had disease in multiple coronary vessels, and over one 
third (16 subjects, or 37 %) had disease involving greater 
than four coronary segments. Multivessel obstructive 
disease (defined as greater than 50  % stenosis in more 
than one coronary artery) was uncommon; only three 
subjects had obstructive disease in two arteries and one 
in all three arteries.
CAC findings
Overall, 60 subjects (61  %) did not have any CAC 
(Table  2). Among the remaining 38 subjects with 
CAC, the majority (24 subjects, or 63  %) had Agatston 
score  <100, with the remaining 14 (37  %) having an 
Agatston score of 100 or greater.
Only five subjects had plaque on coronary CTA despite 
a CAC of zero. The number of affected coronary seg-
ments in these subjects ranged from 1 to 5, and three of 
the five individuals had stenosis greater than 50 %. Two 
of these five subjects had carotid plaque, and one had a 
positive ETT.
Results of carotid ultrasound and exercise treadmill testing
Results from carotid ultrasounds and ETT, stratified by 
the presence of CAD, are presented in Table  3. Mean 
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CIMT was greater in subjects with CAD. Similarly, a 
greater proportion of subjects with CAD had carotid 
plaque than those who did not have any CAD.
Only 8 (8  %) subjects had positive ECG changes dur-
ing the exercise treadmill test, although 20 % of subjects 
did not reach maximal predicted heart rate and one 
Table 1 Patient characteristics
Values given are mean ± standard deviation unless otherwise specified
p Values were calculated using two-tailed t test and Chi squared test; Kruskal–Wallis test was used for comparison of medians
All subjects  
n = 98
Coronary artery  
disease n = 43 (43.9 %)
No coronary artery  
disease n = 55 (56.1 %)
p Value
Demographics
 Age, years 54.5 ± 6.1 56.5 ± 5.8 53.0 ± 5.9 <0.01
 Female sex (#, %) 63 (64.3 %) 24 (55.8 %) 39 (70.9 %) 0.12
Race (#, %)
 Caucasian 64 (65.3 %) 33 (76.7 %) 31 (56.4 %) 0.03
 Black 19 (19.4 %) 4 (9.3 %) 15 (27.3 %)
 Asian 7 (7.1 %) 1 (2.3 %) 6 (10.9 %)
 Other 8 (8.2 %) 5 (11.6 %) 3 (5.5 %)
Clinical data
 Body mass index 29.4 ± 4.7 29.5 ± 4.8 29.3 ± 4.7 0.83
 Abdominal circumference, cm 103.0 ± 12.1 105.0 ± 12.0 101.4 ± 12.1 0.15
 Systolic blood pressure, mmHg 120.9 ± 17.2 125.3 ± 17.3 117.4 ± 16.5 0.02
 Diastolic blood pressure, mmHg 71.9 ± 11.9 73.9 ± 12.3 70.3 ± 11.4 0.15
 Treatment for hypertension (#, %) 64 (65.3) 34 (79.1 %) 30 (54.5 %) 0.01
 Duration of diabetes, years 5.2 ± 3.3 6.5 ± 3.2 4.2 ± 3.0 <0.01
 History of hyperlipidemia (#, %) 55 (56.1 %) 26 (60.5 %) 29 (52.7 %) 0.44
 Family history of coronary artery disease (#, %) 10 (10.2 %) 7 (16.3 %) 3 (5.5 %) 0.08
Smoking status (#, %)
 Current smoker 20 (20.4 %) 10 (23.3 %) 10 (18.2 %) 0.74
 Former smoker 8 (8.2 %) 4 (9.3 %) 4 (7.3 %)
 Never smoker 70 (71.4 %) 29 (67.4 %) 41 (74.5 %)
 Framingham risk score (10-year estimated risk)  
(median, interquartile range)
13.0 % (8.0–16 %) 13.0 % (10–20 %) 13.0  % (8–16 %) 0.07
 2013 AHA/ACC risk calculator (10-year risk of  
atherosclerotic cardiovascular disease)  
(median, interquartile range)
8.2 % (4.0–16.0 %) 13.5 % (5.5–19.7 %) 7.0 % (2.3–13 %) <0.01
 UKPDS risk engine 10-year predicted risk of coronary 
heart disease (median, interquartile range)
11.4 % (5.2–19.4 %) 17.9 % (11.7–26.2 %) 7.2 % (3.8–11.6 %) <0.01
Laboratory data
 Hemoglobin A1c 7.3 ± 1.7 % 8.0 ± 1.7 % 6.8 ± 1.5 % <0.01
 Total cholesterol, mg/dL 193.5 ± 39.7 198.5 ± 46.6 189.7 ± 33.3 0.28
 HDL cholesterol, mg/dL 45.5 ± 13.2 46.7 ± 14.3 44.5 ± 12.5 0.44
 LDL cholesterol, mg/dL 116.7 ± 35.1 120.6 ± 41.4 113.7 ± 29.2 0.33
 Triglycerides, mg/dL (median, interquartile range) 133 (103–198) 148 (101–213) 129 (103–194) 0.46
 Microalbuminuria, mg/24 h (median,  
interquartile range)
5.8 (3.9–11.8) 8.1 (3.9–18.7) 5.4 (3.7–9.0) 0.09
Medications
 Insulin use (#, %) 22 (22.5 %) 15 (34.8 %) 7 (12.7 %) <0.01
 Oral hypoglycemic (#, %) 82 (83.7 %) 39 (90.7 %) 43 (78.2 %) 0.10
 ACE or ARB (#, %) 50 (51.0 %) 27 (62.8 %) 23 (41.8 %) 0.04
 Statin (#, %) 45 (45.9 %) 25 (58.1 %) 20 (26.4 %) 0.03
 Aspirin (#, %) 33 (33.7 %) 19 (44.2 %) 14 (25.5 %) 0.052
Page 5 of 11Rassi et al. Cardiovasc Diabetol  (2016) 15:28 
subject had a non-diagnostic test due to baseline left-
bundle branch block. Two patients had angina during the 
exercise treadmill test. Of these, one had ECG changes 
and considered as a positive test; the other had atypical 
angina without ECG changes and was considered as a 
negative test. The number of METS achieved during the 
test did not differ between the CAD and the non-CAD 
group (8.2 METs vs. 8.7 METS, p =  0.19), though sub-
jects with CAD had a lower Duke Treadmill Score than 
those without CAD (7.1 vs. 9.2, p = 0.03).
Predictive value of screening tests and historical 
parameters for coronary artery disease
The sensitivity and specificity for each testing modal-
ity for the prediction of CAD are shown in Fig. 1. CAC 
offered the best combination of sensitivity and specific-
ity of any evaluated test to detect CAD. Carotid disease, 
by contrast, was only modestly predictive of the presence 
of coronary disease, with sensitivity and specificity in the 
60 % range. ETT, in turn, was not sensitive, but had very 
high specificity. Area under receiver operating character-
istics (ROC) curves for these three modalities were 0.94 
for CAC, 0.64 for carotid ultrasound, and 0.57 for ETT 
(Fig. 1); p value was <0.01 for comparison of CAC with 
other modalities, but was non-significant (0.29) for com-
parison of carotid ultrasound with ETT.
Test characteristics of evaluated historical parameters 
are shown in Table 4. Of these, hypertension and hyper-
lipidemia were the most sensitive, while factors relating 
to severity of diabetes—insulin use, poor glycemic con-
trol, and long duration of diabetes—all were relatively 
insensitive but considerably more specific. Combinations 
of these parameters yielded decreasing sensitivity and 
increasing specificity.
The prevalence of CAD, stratified by insulin use and 
subject age, is presented in Fig.  2. Among non-insu-
lin dependent diabetics, younger subjects had a lower 
prevalence of CAD. However, among insulin-depend-
ent subjects, there was no significant difference in CAD 
prevalence by age. The prevalence of CAD also increased 
by duration of diabetes, as shown in Fig. 3.
Discussion
In this study of asymptomatic diabetic subjects without 
known cardiovascular disease, we showed that there is a 
substantial heterogeneity in the prevalence of subclinical 
coronary disease, as only 44 % of subjects had evidence of 
any plaque by coronary CTA and only 16 % had obstruc-
tive CAD. When coronary CTA was used as the reference 
standard, CAC had the highest sensitivity for detection 
of coronary plaque, while carotid ultrasound, exercise 
treadmill testing, and risk factors, either alone or in com-
bination, had lower sensitivity and specificity. Finally, we 
also found that 33 % of the patients who did not have cor-
onary plaque on CTA had atherosclerotic plaque involv-
ing the carotid arteries.
Prevalence of subclinical coronary disease
Perhaps more notable than the 44  % of subjects with 
coronary disease is the fact that 56  % of the study par-
ticipants had no atherosclerotic plaque in their coronary 
arteries. Coronary CTA is a highly sensitive measure for 
detection of CAD [29, 30], and subjects without plaque 
on CTA correspondingly have a low rate of cardiovascu-
lar events and represent a low risk group [31–33]. This 
finding demonstrates that there is considerable variability 
in cardiac risk amongst diabetics and brings into question 
the classification of diabetes as a coronary heart disease 
equivalent [34]. As a risk stratification tool, screening 
coronary CTA represents an efficient way to define a sub-
set of diabetics at much lower risk for coronary heart dis-
ease, with a number needed to screen of two in order to 
detect one low risk patient in our population. Neverthe-
less, further data are needed regarding the role of preven-
tative therapies (or conversely safety of withholding such 
therapies) in individuals who have T2DM without any 
atherosclerosis on CTA [35, 36].
Table 2 Coronary computed tomography angiography 
findings
Luminal stenosis on coronary CTA Number of subjects (%)
 No stenosis  55 (56.1)
 1–24 %  13 (13.3)
 25–49 %  14 (14.3)
 50–69 %  7 (7.1)
 70 % or greater  9 (9.2)
Number of coronary segments with plaque Number of subjects (%)
 0 segments  55 (56.1)
 1–4 segments  27 (27.6)
 5 or more segments  16 (16.3)
Number of coronary arteries with plaque Number of subjects (%)
 No plaque  55 (56.1)
 1 vessel  16 (16.3)
 2 vessels  15 (15.3)
 3 vessels  12 (12.2)
Number of coronary arteries with obstructive 
disease (≥50 % stenosis)
Number of subjects (%)
 No obstructive disease  82 (83.7)
 1 vessel  12 (12.2)
 2 vessels  3 (3.1)
 3 vessels  1 (1.0)
Coronary artery calcium (Agatston score) Number of subjects (%)
 0  60 (61.2)
 1–99  24 (24.5)
 100 or greater  14 (14.3)
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The proportion of subjects with normal coronary arter-
ies was greater in our population than in most published 
series, which have reported prevalence rates of normal 
CTA in individuals with diabetes ranging from 13–34 % 
of subjects [31, 37–40]. Most published data, however, 
pertain to subjects referred for coronary CTA, who had 
either symptoms concerning for obstructive CAD or 
an abnormal prior stress test. However, even when we 
compared the prevalence of normal CTA in our study to 
other screening populations of asymptomatic diabetics, 
we observed a higher rate in our population. For exam-
ple, in the FACTOR 64 trial, a large, multi-center study 
of coronary CTA in asymptomatic diabetics, 31 % of sub-
jects had a normal CTA. This difference likely reflects the 
fact that FACTOR 64 enrolled a population of diabetics 
with higher cardiovascular risk—when compared to our 
study, the FACTOR 64 population had a greater pro-
portion of men, an older cohort (62 vs. 55  years in our 
study), a longer duration of diabetes (13.9 vs. 5.2 years), 
and a higher rate of insulin use (43 vs. 22 %) [41].
Screening modalities for coronary disease
Among the screening modalities tested in our study, we 
found that CAC scoring had the greatest sensitivity and 
specificity for detection of CAD. The strong test charac-
teristics of calcium scoring are unsurprising, as CAC is 
by definition 100 % specific for coronary plaque and the 
sensitivity is only limited by the presence of exclusively 
non-calcified plaque.
In our sample, the subset whose CAD would be missed 
by calcium scoring—those with coronary plaque but 
Table 3 Results of screening tests stratified by the presence or absence of coronary artery disease
p Values calculated using two-tailed t test, Chi squared test, and Kruskal–Wallis test
MPHR maximal predicted heart rate
Screening tests All subjects  
(n = 98)
Subjects with coronary  
artery disease (n = 43)
Subjects without coronary  
artery disease (n = 55)
p Value
Coronary artery calcium
 0 60 (61.0 %) 5 (11.6 %) 55 (100 %) <0.01
 ≥ 1 (Agatston score) 38 (38.8 %) 38 (88.4 %) 0 (0 %)
Carotid artery ultrasound
 Maximum intima medial thickness 
(IMT), mm
0.75 ± 0.16 0.80 ± 0.20 0.70 ± 0.11 <0.01
 IMT ≥ 1.0 mm (#, %) 11 (11.2 %) 11 (25.6 %) 0 <0.01
 Carotid plaque (#, %)
 No carotid plaque 55 (56.1 %) 18 (41.9 %) 37 (67.3 %) 0.01
 Carotid plaque 43 (43.9 %) 25 (58.4 %) 18 (32.7 %)
 Carotid plaque or IMT ≥ 1.0 mm 44 (44.9 %) 26 (60.5 %) 18 (32.7 %) <0.01
Exercise treadmill test
 ECG test results (#, %)
  Negative 69 (70.4 %) 26 (60.5 %) 43 (78.2 %) 0.04
  Positive 8 (8.2 %) 7 (16.3 %) 1 (1.8 %)
  Negative with <85 % MPHR 20 (20.4 %) 10 (23.3 %) 10 (18.2 %)
  Inconclusive due to LBBB 1 (1.0 %) 0 1 (1.8 %)
 Specific test outcomes
  METS 8.5 ± 2.1 8.2 ± 1.8 8.7 ± 2.4 0.19
  Duke treadmill score 8.3 ± 4.8 7.1 ± 5.0 9.2 ± 4.4 0.03
Fig. 1 Sensitivity and specificity and area under receiver operating 
characteristics curves of different screening modalities for detection 
of coronary artery disease as diagnosed by CTA. CAC scoring was the 
most sensitive and specific test for detection of CAD, with the great-
est area under the ROC curve. Carotid atherosclerosis was defined as 
presence of carotid plaque or CIMT ≥ 1 mm
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without coronary calcium—represented 5 % of the total 
population and 8 % of those with a calcium score of zero. 
Other authors have found higher rates of coronary plaque 
in such patients without any coronary calcium [42]. 
However, since most prior studies have demonstrated an 
extremely low event rate for patients with CAC scores 
of zero, it is unclear whether the presence of exclusively 
non-calcified plaque is associated with any meaningful 
increase in cardiovascular risk [43].
By contrast, exercise treadmill testing was insensitive, 
but quite specific for the presence of coronary disease, a 
conclusion that is in keeping with prior studies of ETT 
in diabetic populations [44–47]. This result is consistent 
with our pathophysiologic understanding of exercise test-
ing, as a positive ETT requires the presence of flow-lim-
iting coronary disease, which implies a more advanced 
coronary lesion. The proportion of subjects with non-
diagnostic testing is also in-line with prior series [44, 48].
Carotid ultrasound had only modest results in both 
sensitivity and specificity, suggesting that this is a less 
useful test for the evaluation of possible coronary heart 
disease in this population. Similar to our findings, Dja-
beri et  al. [49] evaluated 150 asymptomatic diabetics, 
using a lower CIMT cutoff of 0.62  mm, and reported a 
Table 4 Test characteristics of clinical data for prediction of coronary artery disease detected by coronary CTA
Coronary artery disease defined as the presence of any coronary artery plaque on CTA
Definition of positive Frequency  
(total n = 98) (%)
Sensitivity  
(%)
Specificity 
(%)
Clinical variables
 Age ≥50 years Age ≥50 years 75 (77) 83.7 29.1
 Age ≥55 years Age ≥55 years 44 (44.9) 60.5 67.3
High risk clinical criteria
 Hypertension History of hypertension, current treatment, or 
SBP ≥ 140 mmHg
65 (66.3) 81.4 45.5
 Hyperlipidemia LDL cholesterol ≥130 mg/dL or statin therapy 65 (66.3) 76.7 41.8
 Insulin use Current insulin use at time of CTA 22 (22.5) 34.9 87.3
 Poor glycemic control Hemoglobin A1c ≥ 8.0 % 30 (30.6) 46.5 81.8
 Long duration of diabetes Duration of DM > 6 years 33 (33.7) 51.2 80.0
Combinations of high risk clinical criteria
 At least 1 high risk clinical criterion ≥1 criterion defined above 87 (88.8) 95.3 16.4
 At least 2 high risk clinical criteria ≥2 criteria defined above 65 (66.3) 86.0 49.1
 At least 3 high risk clinical criteria ≥3 criteria defined above 38 (38.8) 65.1 81.8
 At least 4 high risk clinical criteria ≥4 criteria defined above 15 (15.3) 27.9 94.5
 At least 5 high risk clinical criteria 5 criteria defined above 8 (8.2) 16.3 98.2
Fig. 2 Prevalence of coronary artery disease as detected by coronary 
CTA stratified by insulin use and age. The prevalence of CAD was 
greater in those over age 50 and those with insulin-dependent 
diabetes
Fig. 3 Prevalence of coronary artery disease as detected by coro-
nary CTA stratified by duration of diabetes. The prevalence of CAD 
increased with increasing duration of diabetes, from 26 % in those 
with diabetes for 3 year or less to 67 % in those with diabetes for 
6 years or longer
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sensitivity and specificity of 76 and 71  %, respectively 
for prediction of any coronary atherosclerosis . Other 
data, mostly in non-diabetic cohorts, have varied on this 
subject. Guarici and colleagues [50], in a moderate risk 
group of symptomatic patients, were able to demonstrate 
CIMT to be independently predictive of obstructive cor-
onary plaque. Other series, by contrast, have not found 
any association between carotid IMT and the presence 
of coronary atherosclerosis by CTA [51]. While there are 
data supporting the association between carotid disease 
(both increased CIMT and carotid plaque) and coronary 
heart disease events [52–55], the presence of carotid dis-
ease likely has a stronger association with stroke; data 
from MESA support this, demonstrating that CAC was a 
much stronger predictor of coronary events than carotid 
ultrasound measures [56].
Carotid disease in the absence of CAD
Interestingly, almost one-third of subjects in our study 
who did not have CAD were found to have carotid artery 
plaque on carotid ultrasound. This represents a poten-
tially intriguing subgroup, as these subjects are low risk—
by virtue of their absence of CAD—from a coronary 
perspective but may have elevated cerebrovascular risk 
[57], especially since diabetes itself is also a risk factor 
for cerebrovascular disease [58]. A similar population of 
patients—with carotid atherosclerosis but without coro-
nary disease—was described in a recent paper by Cohen 
et al. [59] who demonstrated that, in a cohort of 150 pre-
dominantly non-diabetic patients referred for coronary 
CTA, 52 % (33 of 63) of those without any CAD on coro-
nary CTA had carotid plaque.
The exact clinical implications of this finding, however, 
remain unclear, and data are mixed as to whether carotid 
plaque represents a significant cerebrovascular risk factor 
in diabetics above and beyond traditional cardiovascular 
risk factors, as associations between carotid plaque and 
stroke often do not retain statistical significance in multi-
variate models or do so only in certain subsets of patients 
[27, 60, 61]. Carotid atherosclerosis may also herald 
atherosclerosis in other vascular beds, and this popu-
lation may be at increased risk of developing incident 
cardiovascular disease other than stroke. Thus, future 
studies are warranted regarding the prognostic implica-
tions of having carotid plaque in the absence of coronary 
atherosclerosis.
Other markers of risk
Our data also show higher prevalence of CAD in sub-
jects on insulin therapy and an association between the 
presence of CAD and both insulin use and duration of 
diabetes. Subjects receiving insulin and those who had 
carried a diagnosis of diabetes for a longer period of time 
had greater prevalence of CAD, and insulin use was the 
most specific single clinical characteristic for the pres-
ence of coronary disease. Insulin use has previously been 
associated with a greater extent of coronary disease in 
diabetics [31, 62], and duration of diabetes has also been 
associated with worse clinical outcomes [63]. However, 
these two characteristics are rarely highlighted as part of 
a practical, clinical approach to risk stratification, despite 
the presence of a potential pathophysiological link and 
potential clinical utility of those findings [62].
Screening in asymptomatic diabetics
Despite the inherent appeal of early detection of CAD, 
studies of screening for coronary disease in asympto-
matic diabetics have thus far not shown a convincing 
benefit. The Detection of Ischemia in Asymptomatic 
Diabetics (DIAD) study, the first large-scale, randomized 
trial to assess a screening program in asymptomatic dia-
betics, did not find a difference in adverse cardiac out-
comes between screened and unscreened subjects [9]. 
Importantly, though, this study screened subjects with 
SPECT myocardial perfusion imaging, a test less sensitive 
than coronary CTA for detection of CAD, and rates of 
modern medical therapy (statins, aspirin, beta blockers, 
ACE inhibitors) were high and similar in both groups.
The more recent FACTOR-64 trial addressed this 
limitation, using coronary CTA to screen asymptomatic 
diabetics, but similarly did not demonstrate a beneficial 
effect of screening on hard cardiovascular outcomes [41]. 
In this case, just as with DIAD, one of the most salient 
features of the trial was again the low event rate—less 
than 2 % annually—which was substantially less than the 
16 % event rate over 2 years that had been anticipated for 
the study’s power calculation. This difference reflected 
the excellent background medical therapy, with ~75 % of 
study participants having an LDL cholesterol  <100  mg/
dL at baseline.
According to the 2013 American College of Cardiol-
ogy/American Heart Association cholesterol guidelines, 
all diabetics—and therefore all subjects in our study—
should be treated with a moderate or high-intensity sta-
tin [64]. However, statin therapy is not without adverse 
effects [65–68], and it is conceivable that subjects without 
coronary disease may not experience sufficient benefit of 
statin therapy, although further research is required in 
this area. Specifically, what the DIAD and FACTOR-64 
studies did not address was whether subjects with nega-
tive screening tests might safely avoid some preventative 
therapies. Within our cohort, screening with coronary 
CTA identified over 50 % of subjects as having low risk for 
coronary heart disease, suggesting that a significant pro-
portion of individuals who might choose, based on their 
preferences, to focus on lifestyle therapies while deferring 
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pharmacological treatments. Nevertheless, further studies 
are needed regarding the role of statin therapy to reduce 
the lifetime risk of future cardiovascular events in individ-
uals who do not have evidence of coronary plaque.
Limitations
Our study is limited by its small size, composed of 98 
individuals. However, we examined a homogenous and 
well-defined cohort, consisting only of asymptomatic 
subjects with diabetes who had no known cardiovascu-
lar or renal disease. In addition, despite its small size, 
our study is unique as it is the only study of which we are 
aware that has correlated the findings of CAC scoring, 
carotid ultrasonography, ETT and biochemical testing 
against the gold standard of coronary CTA in asympto-
matic individuals with diabetes. We did not incorporate 
data on visceral adiposity or the relative severity of body 
fat, both of which have been shown to be associated 
with subclinical atherosclerosis [69, 70]. Finally, another 
limitation is that our data are cross-sectional and lack 
information on clinical outcomes. However, it is well 
documented that CAC scoring and the presence of CAD 
by CTA are strong predictors of cardiovascular events 
among subjects with diabetes [31, 71–76].
Conclusion
Within this population of asymptomatic subjects with 
diabetes, 56 % did not have any atherosclerotic coronary 
artery disease by coronary CTA, a finding that highlights 
the heterogeneity of cardiovascular risk in diabetics. 
Further research is required to better delineate whether 
there is any clinical role for screening programs to detect 
such individuals. Such screening could be used to indi-
vidualize the intensity of lifestyle and pharmacotherapy 
based on risk level as well as patient preferences. When 
compared to coronary CTA, screening for CAC was the 
most accurate method for detection of subclinical coro-
nary artery disease, as compared to carotid ultrasonog-
raphy or exercise treadmill testing. Finally, a substantial 
proportion of subjects without CAD had detectable 
carotid artery plaque, and further investigation is needed 
to understand both if this represents a population at 
increased risk of adverse events and whether any inter-
ventions might decrease this risk.
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